Evidence map›Paper›PMID 41690480›Full record

ReviewJournal of controlled release : official journal of the Controlled Release Society2026

Microbial medicines: Unlocking the therapeutic potential of the microbiome in cancer treatment.

Abram Canowitz, Nitin S Kamble, Nathan Muck, Komalpreet Kaur, Nathaniel Garay, Priyanka Bellala, Bhavesh Babulal Gabani, Nalinikanth Kotagiri

Abstract readReview
In one paragraph

Review in Journal of controlled release : official journal of the Controlled Release Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Vitamin D3 contribution to systemic and local control ofFrontiers in molecular biosciences · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Abram CanowitzDepartment of Pharmaceutical Sciences, UC James L. Winkle College of Pharmacy, The University of Cincinnati, Cincinnati, OH 45220, USA.
Nitin S KambleDepartment of Pharmaceutical Sciences, UC James L. Winkle College of Pharmacy, The University of Cincinnati, Cincinnati, OH 45220, USA.
Nathan MuckDepartment of Pharmaceutical Sciences, UC James L. Winkle College of Pharmacy, The University of Cincinnati, Cincinnati, OH 45220, USA.
Komalpreet KaurDepartment of Pharmaceutical Sciences, UC James L. Winkle College of Pharmacy, The University of Cincinnati, Cincinnati, OH 45220, USA.
Nathaniel GarayDepartment of Pharmaceutical Sciences, UC James L. Winkle College of Pharmacy, The University of Cincinnati, Cincinnati, OH 45220, USA.
Priyanka BellalaDepartment of Pharmaceutical Sciences, UC James L. Winkle College of Pharmacy, The University of Cincinnati, Cincinnati, OH 45220, USA.
Bhavesh Babulal GabaniDepartment of Pharmaceutical Sciences, UC James L. Winkle College of Pharmacy, The University of Cincinnati, Cincinnati, OH 45220, USA.
Nalinikanth KotagiriDepartment of Pharmaceutical Sciences, UC James L. Winkle College of Pharmacy, The University of Cincinnati, Cincinnati, OH 45220, USA. Electronic address: kotaginh@ucmail.uc.edu.

Funding

Siderophore based molecular imaging of pulmonary infectionsR01HL168588 · NHLBI · UNIVERSITY OF CINCINNATI · PI Nalinikanth Kotagiri · 2023 to 2026
$2.4M
Genetically-encoded molecular imaging of genome-edited immune cellsR01CA279962 · NCI · UNIVERSITY OF CINCINNATI · PI Nalinikanth Kotagiri · 2024 to 2026
$2.3M
American Heart Association-American Stroke Association 24TPA1303687Congressionally Directed Medical Research Program ME200246NCI NIH HHS R01 CA279962NHLBI NIH HHS R01 HL168588
6 · The paper itself

Abstract

Microorganisms have had an established relationship with the maintenance of human health, and recent advancements in genetic engineering and synthetic biology have allowed the development of engineered microbes as targeted disease treatment. This review evaluates the rising use of microorganisms as therapeutic agents, particularly in the treatment of cancer. These engineered microbes are able to detect disease markers and precisely deliver therapeutic payloads to affected sites. These bacterial-based therapeutics show remarkable promise against cancers like pancreatic, breast, lung, and colorectal cancers by targeting tumor microenvironments and enhancing antitumor immunity. While obstacles still remain, such as interindividual variability, safety concerns, and regulatory barriers, the medicinal potential of microbial therapeutics is promising. Future research should focus on furthering the understanding of microbe-host interaction mechanisms and refining bacterial engineering techniques to continue to develop more precise and effective therapies. Ultimately, harnessing the power of microorganisms has the potential to revolutionize the treatment of complex diseases, such as cancer.

Indexed as

MicrobiotaNeoplasmsAnimalsBacteriaHumansTumor MicroenvironmentCancermicrobial engineeringmicrobiomesynthetic biologytherapeutics

Identifiers

PMID41690480
PMCPMC13229583

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.